Invent Medic is formed to further develop Jan Clarén’s innovative product TVS that relieves female incontinence.
Further development together with Lars-Olof Henriksson provides an anatomically functional product.
The first patent application is filed.
The first prototypes are developed for clinical evaluation.
Patent approval is obtained in Sweden, and Lars Persson is engaged as chairman of the board.
Small-scale production begins.
Discussions with market stakeholders indicate interest in a CE marked product.
The company decides to launch products on its own, and Karin Bryder is appointed as CEO.
Grants of 0.5 MSEK are received from the government agency Vinnova for market research.
A directed share issue of approximately 4 MSEK is conducted.
A share issue of 9 MSEK is conducted, and the company is listed on Aktietorget (later renamed to Spotlight Stock Market).
Large-scale production is ensured through the leading European manufacturer TMRubber.
Patent approval is obtained in the United States.
Patent approval is obtained in Europe.
Share issue of 10.2 MSEK is conducted.
The clinical study with Efemia is completed with significant positive results.
A share issue of 19.3 MSEK is conducted.
Efemia receives CE marking and is launched in Sweden under the Arcamea brand name.
A post-launch user study is initiated in collaboration with Aller Media.
Efemia is launched in Denmark, Norway, the UK and Germany.
The work with evaluating the next Invent Medic product is intensified.
Invent Medic submits offers for Efemia in public procurements processes in Sweden.
Västra Götaland becomes the first health care region in Sweden to order Efemia in accordance with an agreement valid until a potential public procurement process is finalised.